StockMacro
Menu

Incyte Genomics

$114.62 +18% in 6 monthsMarket cap $23.4B

INCY on XNAS, Health Care, Incyte Genomics Inc, job postings

Measures activity, not value. Not investment advice.

Revenue up 25% to $6B but net income fell 66% while insiders sold $33.3M in 90 days.

  • GoodInstitutional filers rose to 889 from 837, up 6.2%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Industry
Services-commercial physical & biological research (Health Care)
Employees
2,844
Website
incyte.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.6B, net loss $784.8M.
Quarter to 31 Dec 2021: revenue $862.9M, net income $563.9MQuarter to 31 Dec 2021: revenue $862.9M, net income $563.9MQuarter to 31 Mar 2022: revenue $733.2M, net income $38.0MQuarter to 31 Mar 2022: revenue $733.2M, net income $38.0MQuarter to 30 Jun 2022: revenue $911.4M, net income $161.4MQuarter to 30 Jun 2022: revenue $911.4M, net income $161.4MQuarter to 30 Sep 2022: revenue $823.3M, net income $112.8MQuarter to 30 Sep 2022: revenue $823.3M, net income $112.8MQuarter to 31 Dec 2022: revenue $926.7M, net income $28.5MQuarter to 31 Dec 2022: revenue $926.7M, net income $28.5MQuarter to 31 Mar 2023: revenue $808.7M, net income $21.7MQuarter to 31 Mar 2023: revenue $808.7M, net income $21.7MQuarter to 30 Jun 2023: revenue $954.6M, net income $203.5MQuarter to 30 Jun 2023: revenue $954.6M, net income $203.5MQuarter to 30 Sep 2023: revenue $919.0M, net income $171.3MQuarter to 30 Sep 2023: revenue $919.0M, net income $171.3MQuarter to 31 Dec 2023: revenue $1.0B, net income $201.1MQuarter to 31 Dec 2023: revenue $1.0B, net income $201.1MQuarter to 31 Mar 2024: revenue $880.9M, net income $169.5MQuarter to 31 Mar 2024: revenue $880.9M, net income $169.5MQuarter to 30 Jun 2024: revenue $1.0B, net income -$444.6MQuarter to 30 Jun 2024: revenue $1.0B, net income -$444.6MQuarter to 30 Sep 2024: revenue $1.1B, net income $106.5MQuarter to 30 Sep 2024: revenue $1.1B, net income $106.5MQuarter to 31 Dec 2024: revenue $1.2B, net income $201.2MQuarter to 31 Dec 2024: revenue $1.2B, net income $201.2MQuarter to 31 Mar 2025: revenue $1.1B, net income $158.2MQuarter to 31 Mar 2025: revenue $1.1B, net income $158.2MQuarter to 30 Jun 2025: revenue $1.2B, net income $405.0MQuarter to 30 Jun 2025: revenue $1.2B, net income $405.0MQuarter to 30 Sep 2025: revenue $1.4B, net income $424.2MQuarter to 30 Sep 2025: revenue $1.4B, net income $424.2MQuarter to 31 Dec 2025: revenue $1.5B, net income $299.3MQuarter to 31 Dec 2025: revenue $1.5B, net income $299.3MQuarter to 31 Mar 2026: revenue $1.3B, net income $303.3MQuarter to 31 Mar 2026: revenue $1.3B, net income $303.3MQuarter to 30 Jun 2026: revenue $1.7B, net income $585.6MQuarter to 30 Jun 2026: revenue $1.7B, net income $585.6MQuarter to 30 Sep 2026: revenue $1.6B, net income -$784.8MQuarter to 30 Sep 2026: revenue $1.6B, net income -$784.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.7B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.6B-$784.8M
30 Jun 2026$1.7B$585.6M
31 Mar 2026$1.3B$303.3M
31 Dec 2025$1.5B$299.3M
30 Sep 2025$1.4B$424.2M
30 Jun 2025$1.2B$405.0M
31 Mar 2025$1.1B$158.2M
31 Dec 2024$1.2B$201.2M
30 Sep 2024$1.1B$106.5M
30 Jun 2024$1.0B-$444.6M
31 Mar 2024$880.9M$169.5M
31 Dec 2023$1.0B$201.1M
30 Sep 2023$919.0M$171.3M
30 Jun 2023$954.6M$203.5M
31 Mar 2023$808.7M$21.7M
31 Dec 2022$926.7M$28.5M
30 Sep 2022$823.3M$112.8M
30 Jun 2022$911.4M$161.4M
31 Mar 2022$733.2M$38.0M
31 Dec 2021$862.9M$563.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $6.0B $4.8B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +25% +3.4%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $403.4M $1.2B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.88 $5.90
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 92.7% 92.9% 63.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 10.4% 30.8% 4.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 6.7% 24.7% 1.0%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 7.8% -16.5%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $3.9B $2.9B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.00
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $27.68
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 57.9 57.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.9 4.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 4.4
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.1 4.4

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Incyte GenomicsINCY (this company) $23.4B57.93.9+25%6.7%
MedpaceMEDP $17.1B33.06.0+20%18.2%
Charles River Laboratories InternationalCRL $15.1B3753.8-1.2%1.0%
IQVIAIQV $40.5B29.12.3+8.8%8.1%
AbsciABSI $1.3Bloss872-47%–
United TherapeuticsUTHR $23.6B19.27.4+1.9%38.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$33.3M

bought $0, sold $33.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.2%

889 13F filers vs 837

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

199.4M shares held by 13F filers (30 Sep 2026) of 203.8M outstanding (22 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.2%

10.6M shares sold short (30 Oct 2026) of 203.8M outstanding (22 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.6

10.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.2%

10.0M shares sold short in the report before, 10.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 65%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

98

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+15%

39 vs 34 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+14%

$1.6B vs $1.4B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.1M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

2

2 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

2 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $114.62 on 20 Nov 2026, +13% over 12 months (12-month range $90.30 to $129.93)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $67.7M in the last 12 months (the 12 months before: -$28.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 39 published in the last 12 months, +18% on the 12 months before.
Revenue per quarter. Revenue $1.6B in the latest quarter, +14% on a year earlier.
Capital spending per quarter. Capital spending $21.3M in the latest quarter, -38% on a year earlier.
Institutional holders (13F filers). 889 13F filers reported holding it in the latest 13F quarter, +32% on a year earlier.
Lobbying spend. Lobbying spend: $2.1M published in the last 12 months, +49% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Oct 2026Lobbying filinglobbying engagement terminated (LMH STRATEGIC SOLUTIONS)
30 Mar 20268-K and other filingsDirector or officer change
26 Mar 20268-K and other filingsDirector or officer change
26 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 129 vs usual 70.50 (2025-12-31); 1.6x the same period a year earlier
12 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 1.5B vs usual 1.1B (2025-12-31); 1.3x the same period a year earlier
22 Dec 2025Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
12 Dec 20258-K and other filingsDirector or officer change
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 112 vs usual 64.50 (2025-09-30); 1.6x the same period a year earlier
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2025-09-30)
3 Oct 20258-K and other filingsDirector or officer change
7 Aug 20258-K and other filingsDirector or officer change
16 Jul 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
27 Jun 20258-K and other filingsDirector or officer change
11 Jun 20258-K and other filingsDirector or officer change
11 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jan 20258-K and other filingsDirector or officer change
10 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Jul 2024Sharp changeLobbying on a new issue: lobbying on a new issue: INS (2024-06-30)
16 Jul 2024Sharp changeShort interest spike: short interest spike, 16.9M vs usual 7.7M (2024-06-28); 2.9x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 18.7M vs usual 7.5M (2024-06-14); 2.9x the same period a year earlier
22 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: HOM (2024-03-31)
24 Oct 2023Sharp changeLobbying spend jump: lobbying spend jump, 360K vs usual 210K (2023-09-30); 1.6x the same period a year earlier
20 Oct 2023Sharp changeLobbying on a new issue: lobbying on a new issue: GOV (2023-09-30)
12 Sep 20238-K and other filingsDirector or officer change
15 Jun 20238-K and other filingsDirector or officer change
15 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2023Sharp changeLobbying on a new issue: lobbying on a new issue: NAT (2023-03-31)
20 Oct 2022Sharp changeLobbying on a new issue: lobbying on a new issue: CPT (2022-09-30)
4 Oct 20228-K and other filingsDirector or officer change
4 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jul 2022Sharp changeLobbying on a new issue: lobbying on a new issue: TAX (2022-06-30)
21 Apr 20228-K and other filingsDirector or officer change
21 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jan 20228-K and other filingsDirector or officer change
14 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: $115.1M published
Month from 1 Jan 2022: -$2.1M published
Month from 1 Feb 2022: $142.1M published
Month from 1 Mar 2022: $28.1M published
Month from 1 Apr 2022: -$3.7M published
Month from 1 Jul 2022: -$817K published
Month from 1 Dec 2022: -$1.5M published
Month from 1 Jan 2023: -$3.1M published
Month from 1 Feb 2023: -$5.2M published
Month from 1 Aug 2023: -$1.4M published
Month from 1 Sep 2023: -$550K published
Month from 1 Dec 2023: -$79K published
Month from 1 Jan 2024: -$525K published
Month from 1 Jun 2024: -$1.2M published
Month from 1 Jul 2024: -$1.7M published
Month from 1 Aug 2024: -$704K published
Month from 1 Sep 2024: -$587K published
Month from 1 Nov 2024: -$293K published
Month from 1 Dec 2024: -$547K published
Month from 1 Jan 2025: -$898K published
Month from 1 Mar 2025: -$2.4M published
Month from 1 Jun 2025: -$228K published
Month from 1 Jul 2025: -$3.3M published
Month from 1 Aug 2025: -$69K published
Month from 1 Sep 2025: -$74K published
Month from 1 Oct 2025: -$376K published
Month from 1 Nov 2025: -$20.8M published
Month from 1 Dec 2025: -$8.9M published
Month from 1 Jan 2026: -$2.8M published
Month from 1 Feb 2026: -$1.9M published
Month from 1 Mar 2026: -$1.8M published
Month from 1 Apr 2026: -$1.8M published
Month from 1 May 2026: -$1.6M published
Month from 1 Jun 2026: -$264K published
Month from 1 Jul 2026: -$3.5M published
Month from 1 Aug 2026: -$11.9M published
Month from 1 Sep 2026: -$2.8M published
Month from 1 Oct 2026: -$298K published
Month from 1 Nov 2026: -$30.2M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 3 published
Quarter from 1 Apr 2022: 7 published
Quarter from 1 Jul 2022: 15 published
Quarter from 1 Oct 2022: 7 published
Quarter from 1 Jan 2023: 4 published
Quarter from 1 Apr 2023: 6 published
Quarter from 1 Jul 2023: 12 published
Quarter from 1 Oct 2023: 9 published
Quarter from 1 Jan 2024: 7 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 14 published
Quarter from 1 Oct 2024: 9 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 6 published
Quarter from 1 Jul 2025: 21 published
Quarter from 1 Oct 2025: 5 published
Quarter from 1 Jan 2026: 9 published
Quarter from 1 Apr 2026: 3 published
Quarter from 1 Jul 2026: 17 published
Quarter from 1 Oct 2026: 10 published
Revenue per quarter
Quarter ended 31 Dec 2021: $862.9M, +9.3% on a year earlier; public on 9 Feb 2022
Quarter ended 31 Mar 2022: $733.2M, +21% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $911.4M, +29% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $823.3M, +1.3% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $926.7M, +7.4% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $808.7M, +10% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $954.6M, +4.7% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $919.0M, +12% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $1.0B, +9.3% on a year earlier; public on 14 Feb 2024
Quarter ended 31 Mar 2024: $880.9M, +8.9% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $1.0B, +9.3% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $1.1B, +24% on a year earlier; public on 30 Oct 2024
Quarter ended 31 Dec 2024: $1.2B, +16% on a year earlier; public on 11 Feb 2025
Quarter ended 31 Mar 2025: $1.1B, +20% on a year earlier; public on 30 Apr 2025
Quarter ended 30 Jun 2025: $1.2B, +16% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $1.4B, +20% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $1.5B, +28% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $1.3B, +21% on a year earlier; public on 29 Apr 2026
Quarter ended 30 Jun 2026: $1.7B, +38% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $1.6B, +14% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $34.5M, -33% on a year earlier; public on 9 Feb 2022
Quarter ended 31 Mar 2022: $17.0M, -65% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $11.7M, -82% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $27.8M, -14% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $21.3M, -38% on a year earlier; public on 8 Feb 2023
Institutional holders (13F filers)
31 Dec 2021 report: 476; public on 14 Feb 2022
31 Mar 2022 report: 493; public on 16 May 2022
30 Jun 2022 report: 493; public on 15 Aug 2022
30 Sep 2022 report: 483; public on 14 Nov 2022
31 Dec 2022 report: 505; public on 14 Feb 2023
31 Mar 2023 report: 505; public on 15 May 2023
30 Jun 2023 report: 481; public on 14 Aug 2023
30 Sep 2023 report: 475; public on 14 Nov 2023
31 Dec 2023 report: 510; public on 14 Feb 2024
31 Mar 2024 report: 549; public on 15 May 2024
30 Jun 2024 report: 538; public on 14 Aug 2024
30 Sep 2024 report: 543; public on 14 Nov 2024
31 Dec 2024 report: 617; public on 14 Feb 2025
31 Mar 2025 report: 589; public on 15 May 2025
30 Jun 2025 report: 625; public on 14 Aug 2025
30 Sep 2025 report: 673; public on 14 Nov 2025
31 Dec 2025 report: 780; public on 17 Feb 2026
31 Mar 2026 report: 790; public on 15 May 2026
30 Jun 2026 report: 837; public on 14 Aug 2026
30 Sep 2026 report: 889; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $110K published
Quarter from 1 Apr 2022: $280K published
Quarter from 1 Jul 2022: $200K published
Quarter from 1 Oct 2022: $220K published
Quarter from 1 Jan 2023: $180K published
Quarter from 1 Apr 2023: $350K published
Quarter from 1 Jul 2023: $220K published
Quarter from 1 Oct 2023: $360K published
Quarter from 1 Jan 2024: $460K published
Quarter from 1 Apr 2024: $200K published
Quarter from 1 Jul 2024: $300K published
Quarter from 1 Oct 2024: $220K published
Quarter from 1 Jan 2025: $350K published
Quarter from 1 Apr 2025: $240K published
Quarter from 1 Jul 2025: $520K published
Quarter from 1 Oct 2025: $330K published
Quarter from 1 Jan 2026: $530K published
Quarter from 1 Apr 2026: $480K published
Quarter from 1 Jul 2026: $750K published
Quarter from 1 Oct 2026: $380K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $1.8B (30 Sep 2026), 3.6× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $67.7M in the last 12 months (the 12 months before: -$28.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 39 published in the last 12 months, +18% on the 12 months before.
  • Revenue per quarter: Revenue $1.6B in the latest quarter, +14% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 7 sales, $33.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Steven H SteinCMO & Head of Late-Stage Dev.Sellplanned in advance (10b5-1); after exercising options576$121.98$70KForm 4
18 Nov 2026Pablo J CagnoniPresident, Global Head of R&DSellplanned in advance (10b5-1); after exercising options2,642$120.96$320KForm 4
17 Nov 2026Lee HeesonEVP, Head of Incyte IntlSellplanned in advance (10b5-1)10,694$120.82$1.3MForm 4
10 Nov 2026Steven H SteinCMO & Head of Late-Stage Dev.Sellplanned in advance (10b5-1); after exercising options240,193$118.39$28.4MForm 4
5 Nov 2026Thomas TrayPrincipal Accounting OfficerSellplanned in advance (10b5-1)610$118.96$73KForm 4
19 Oct 2026Pablo J CagnoniPresident, Global Head of R&DSellplanned in advance (10b5-1); after exercising options2,642$112.71$298KForm 4
17 Sep 2026Pablo J CagnoniPresident, Global Head of R&DSellplanned in advance (10b5-1); after exercising options23,218$120.49$2.8MForm 4
20 Aug 2026Pablo J CagnoniPresident, Global Head of R&DSellplanned in advance (10b5-1)10,801$125.56$1.4MForm 4

889 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 130 opened a position, 78 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Baker Bros. Advisors LP30.8M15.1%$3.7B+3220%
BlackRock, Inc.19.1M9.38%$2.3B+1.1M+6.1%
Vanguard Capital Management LLC11.2M5.51%$1.4B+199K+1.8%
Dodge & Cox10.1M4.94%$1.2B-1.9M-16%
State Street Corp9.9M4.84%$1.2B+136K+1.4%
Vanguard Portfolio Management LLC7.8M3.81%$943.3M-18K-0.2%
AQR Capital Management LLC5.6M2.74%$677.4M+261K+4.9%
Geode Capital Management, LLC4.9M2.40%$591.3M+140K+2.9%
Invesco Ltd.4.1M2.03%$502.0M+57K+1.4%
LSV Asset Management3.9M1.90%-242K-5.9%

Company events

All 42 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Mar 2026Director or officer change8-K
26 Mar 2026Director or officer change8-K
12 Dec 2025Director or officer change8-K
3 Oct 2025Director or officer change8-K
7 Aug 2025Director or officer change8-K
27 Jun 2025Director or officer change8-K
11 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
10 Jan 2025Director or officer change8-K

98 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 22%, Legal, policy & compliance 14%, Operations & administration 12%, Test, quality & reliability 9%.

PostedJobLocation
20 Nov 2026Director, Executive Compensation & HR AnalyticsPeople & recruitingWilmington, Delaware
19 Nov 2026Senior Manager, Security OperationsSecurityChadds Ford, Pennsylvania
19 Nov 2026Applications / CRM Sr AnalystOperations & administrationChadds Ford, Pennsylvania
19 Nov 2026Medical Science Liaison IAI - Münster, Dortmund, Bielefeld (m/f/d)Program & project managementGermany Remote Location, Germany
18 Nov 2026Manager, FP&A – Central Reporting and G&A Business PartneringFinance & accountingWilmington, Delaware
18 Nov 2026Specialist QC Stability and Raw MaterialsSupply chain & procurementYverdon-les-Bains, Switzerland
12 Nov 2026Quality Value & Lean Process Excellence, InternTest, quality & reliabilityMorges, Switzerland
12 Nov 2026Digital Transformation & Process Excellence, InternOperations & administrationMorges, Switzerland

Reported lobbying spend: $380K in Q3 2026, $750K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedLMH Strategic Solutionsfor Incyte CorporationHealthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.Health issues, PharmacyFiling
11 Nov 2025NewCheckmate Government Relationsfor Incyte CorporationIssues relating to CMS coverage and reimbursement policies.Medicare/MedicaidFiling
1 Jul 2025NewLMH Strategic Solutionsfor Incyte CorporationPrescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.Pharmacy, Medicare/MedicaidFiling
1 Jan 2021NewIncyte Corporationits own lobbyistsIssues related to 340B (contract pharmacy provisions); drug pricing; out of pocket costs in Medicare Part D and importationMedicare/MedicaidFiling
1 Dec 2020NewTiber Creek Groupfor Incyte CorporationIssues affecting the pharmaceutical industry.Health issuesFiling
11 Nov 2019NewW Strategies, LLCfor Incyte CorporationIssues around Medicare Part D.Medicare/MedicaidFiling
1 Nov 2019NewAvenue Solutionsfor Incyte CorporationValue of prescription drugs; Medicare Part DMedicare/MedicaidFiling

The 5 newest of 6 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Incyte Genomics (INCY): reported revenue of $1.5B for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it saw 129 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 5 days.

  • Financials: Quarterly revenue change, became public on 12 Feb 2026
  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
2023-12-31: $1.0B2024-03-31: $880.9M2024-06-30: $1.0B2024-09-30: $1.1B2024-12-31: $1.2B2025-03-31: $1.1B2025-06-30: $1.2B2025-09-30: $1.4B2025-12-31: $1.5B
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $1.1B
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 12 Feb 2026

Incyte Genomics reported revenue of $1.5B for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

This period
$1.5B (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$1.1B
Typical spread (median absolute deviation)
$82.7M
How far from its usual level
+3.4
Same quarter last year
$1.2B
History used
3,562 days
2023-12-31: $1.0B2024-03-31: $880.9M2024-06-30: $1.0B2024-09-30: $1.1B2024-12-31: $1.2B2025-03-31: $1.1B2025-06-30: $1.2B2025-09-30: $1.4B2025-12-31: $1.5B
the quarter ended 31 Dec 20258 earlier quartersnormal: $1.1B

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

Incyte Genomics saw 129 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

This period
129 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
70.5
Typical spread (median absolute deviation)
10.5
How far from its usual level
+3.8
Same quarter last year
81
History used
4,475 days
2023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 1122025-12-31: 129
the quarter ended 31 Dec 20258 earlier quartersnormal: 70.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

18 Nov 2025confirmed

Confirmed across sources Institutional holdings and Lobbying

Incyte Genomics (INCY): lobbying on a new issue, while it saw 112 13F filers open a new position in the quarter ended 30 Sep 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 29 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Oct 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
2023-09-30: 452023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 112
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: 64.5
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 20 Oct 2025

Incyte Genomics lobbying on a new issue.

New
['PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4690935

Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

Incyte Genomics saw 112 13F filers open a new position in the quarter ended 30 Sep 2025, 1.6× the same quarter last year.

This period
112 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
64.5
Typical spread (median absolute deviation)
8
How far from its usual level
+4.0
Same quarter last year
68
History used
4,383 days
2023-09-30: 452023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 112
the quarter ended 30 Sep 20258 earlier quartersnormal: 64.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

22 Jul 2024confirmed

Confirmed across sources Lobbying and Short interest and volume

Incyte Genomics (INCY): had 18.7M shares sold short in the 14 Jun 2024 report, 2.9× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.

  • Short interest and volume: Short interest spike, became public on 27 Jun 2024
  • Short interest and volume: Short interest spike, became public on 11 Jul 2024
  • Lobbying: Lobbying on a new issue, became public on 22 Jul 2024
2023-06-15: 6.4M2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M
The 14 Jun 2024 report against the 24 reports before it. this reportearliernormal: 7.5M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 27 Jun 2024

Incyte Genomics had 18.7M shares sold short in the 14 Jun 2024 report, 2.9× the same report last year.

This period
18.7M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
7.5M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+6.5
Same report last year
6.4M
History used
2,359 days
2023-06-15: 6.4M2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M
the 14 Jun 2024 report24 earlier reportsnormal: 7.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jul 2024

Incyte Genomics had 16.9M shares sold short in the 28 Jun 2024 report, 2.9× the same report last year.

This period
16.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.9
Same report last year
5.9M
History used
2,373 days
2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M2024-06-28: 16.9M
the 28 Jun 2024 report24 earlier reportsnormal: 7.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 22 Jul 2024

Incyte Genomics lobbying on a new issue.

New
['INS']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6410059

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Oct 2026Lobbying record

    INCYTE CORPORATION: lobbying engagement terminated (LMH STRATEGIC SOLUTIONS) (dated 30 Jun 2026)

  2. 30 Mar 2026Filings record

    Director or officer change

  3. 26 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 26 Mar 2026Filings record

    Director or officer change

  5. 17 Feb 2026several at once

    reported revenue of $1.5B for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it saw 129 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 5 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 12 Feb 2026

    Incyte Genomics reported revenue of $1.5B for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

    This period
    $1.5B (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $1.1B
    Typical spread (median absolute deviation)
    $82.7M
    How far from its usual level
    +3.4
    Same quarter last year
    $1.2B
    History used
    3,562 days
    2023-12-31: $1.0B2024-03-31: $880.9M2024-06-30: $1.0B2024-09-30: $1.1B2024-12-31: $1.2B2025-03-31: $1.1B2025-06-30: $1.2B2025-09-30: $1.4B2025-12-31: $1.5B
    the quarter ended 31 Dec 20258 earlier quartersnormal: $1.1B

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    Incyte Genomics saw 129 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    This period
    129 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    70.5
    Typical spread (median absolute deviation)
    10.5
    How far from its usual level
    +3.8
    Same quarter last year
    81
    History used
    4,475 days
    2023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 1122025-12-31: 129
    the quarter ended 31 Dec 20258 earlier quartersnormal: 70.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  6. 17 Feb 2026Institutional holdings change

    saw 129 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    Same quarter last year: 81; its normal quarter is 70.5.

    See the evidence
    This period
    129 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    70.5
    Typical spread (median absolute deviation)
    10.5
    How far from its usual level
    +3.8
    Same quarter last year
    81
    History used
    4,475 days
    2023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 1122025-12-31: 129
    the quarter ended 31 Dec 20258 earlier quartersnormal: 70.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  7. 12 Feb 2026Financials change

    reported revenue of $1.5B for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

    Same quarter last year: $1.2B; its normal quarter is $1.1B.

    See the evidence
    This period
    $1.5B (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $1.1B
    Typical spread (median absolute deviation)
    $82.7M
    How far from its usual level
    +3.4
    Same quarter last year
    $1.2B
    History used
    3,562 days
    2023-12-31: $1.0B2024-03-31: $880.9M2024-06-30: $1.0B2024-09-30: $1.1B2024-12-31: $1.2B2025-03-31: $1.1B2025-06-30: $1.2B2025-09-30: $1.4B2025-12-31: $1.5B
    the quarter ended 31 Dec 20258 earlier quartersnormal: $1.1B

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  8. 22 Dec 2025Lobbying record

    INCYTE CORPORATION: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 11 Nov 2025)

  9. 12 Dec 2025Filings record

    Director or officer change

  10. 18 Nov 2025several at once

    lobbying on a new issue, while it saw 112 13F filers open a new position in the quarter ended 30 Sep 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 29 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 20 Oct 2025

    Incyte Genomics lobbying on a new issue.

    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690935

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    Incyte Genomics saw 112 13F filers open a new position in the quarter ended 30 Sep 2025, 1.6× the same quarter last year.

    This period
    112 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    64.5
    Typical spread (median absolute deviation)
    8
    How far from its usual level
    +4.0
    Same quarter last year
    68
    History used
    4,383 days
    2023-09-30: 452023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 112
    the quarter ended 30 Sep 20258 earlier quartersnormal: 64.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  11. 14 Nov 2025Institutional holdings change

    saw 112 13F filers open a new position in the quarter ended 30 Sep 2025, 1.6× the same quarter last year.

    Same quarter last year: 68; its normal quarter is 64.5.

    See the evidence
    This period
    112 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    64.5
    Typical spread (median absolute deviation)
    8
    How far from its usual level
    +4.0
    Same quarter last year
    68
    History used
    4,383 days
    2023-09-30: 452023-12-31: 602024-03-31: 732024-06-30: 612024-09-30: 682024-12-31: 812025-03-31: 572025-06-30: 902025-09-30: 112
    the quarter ended 30 Sep 20258 earlier quartersnormal: 64.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690935
  13. 3 Oct 2025Filings record

    Director or officer change

  14. 7 Aug 2025Filings record

    Director or officer change

  15. 16 Jul 2025Lobbying record

    INCYTE CORPORATION: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jul 2025)

  16. 27 Jun 2025Filings record

    Director or officer change

  17. 11 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 11 Jun 2025Filings record

    Director or officer change

  19. 10 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 10 Jan 2025Filings record

    Director or officer change

  21. 22 Jul 2024several at once

    had 18.7M shares sold short in the 14 Jun 2024 report, 2.9× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 27 Jun 2024

    Incyte Genomics had 18.7M shares sold short in the 14 Jun 2024 report, 2.9× the same report last year.

    This period
    18.7M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    7.5M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +6.5
    Same report last year
    6.4M
    History used
    2,359 days
    2023-06-15: 6.4M2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M
    the 14 Jun 2024 report24 earlier reportsnormal: 7.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jul 2024

    Incyte Genomics had 16.9M shares sold short in the 28 Jun 2024 report, 2.9× the same report last year.

    This period
    16.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    7.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.9
    Same report last year
    5.9M
    History used
    2,373 days
    2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M2024-06-28: 16.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 7.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 22 Jul 2024

    Incyte Genomics lobbying on a new issue.

    New
    ['INS']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6410059

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  22. 22 Jul 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['INS']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6410059
  23. 11 Jul 2024Short interest and volume change

    had 16.9M shares sold short in the 28 Jun 2024 report, 2.9× the same report last year.

    Same report last year: 5.9M; its normal report is 7.7M.

    See the evidence
    This period
    16.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    7.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.9
    Same report last year
    5.9M
    History used
    2,373 days
    2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M2024-06-28: 16.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 7.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Jun 2024Short interest and volume change

    had 18.7M shares sold short in the 14 Jun 2024 report, 2.9× the same report last year.

    Same report last year: 6.4M; its normal report is 7.5M.

    See the evidence
    This period
    18.7M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    7.5M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +6.5
    Same report last year
    6.4M
    History used
    2,359 days
    2023-06-15: 6.4M2023-06-30: 5.9M2023-07-14: 5.7M2023-07-31: 4.9M2023-08-15: 6.0M2023-08-31: 5.7M2023-09-15: 6.5M2023-09-29: 7.5M2023-10-13: 8.0M2023-10-31: 9.1M2023-11-15: 9.3M2023-11-30: 8.3M2023-12-15: 7.0M2023-12-29: 6.3M2024-01-12: 5.2M2024-01-31: 7.0M2024-02-15: 8.7M2024-02-29: 7.8M2024-03-15: 7.9M2024-03-28: 8.1M2024-04-15: 8.3M2024-04-30: 9.6M2024-05-15: 7.5M2024-05-31: 11.7M2024-06-14: 18.7M
    the 14 Jun 2024 report24 earlier reportsnormal: 7.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 22 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['HOM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6540989
  26. 20 Oct 2023Lobbying change

    reported $360K of lobbying spend for the quarter ended 30 Sep 2023, 1.6× the same quarter last year.

    Same quarter last year: $220K; its normal quarter is $210K.

    See the evidence
    This period
    $360K (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $210K
    Typical spread (median absolute deviation)
    $25K
    How far from its usual level
    +4.0
    Same quarter last year
    $220K
    History used
    1,369 days
    2021-09-30: $190K2021-12-31: $110K2022-03-31: $280K2022-06-30: $200K2022-09-30: $220K2022-12-31: $180K2023-03-31: $350K2023-06-30: $220K2023-09-30: $360K
    the quarter ended 30 Sep 20238 earlier quartersnormal: $210K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  27. 20 Oct 2023Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['GOV']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12618999
  28. 12 Sep 2023Filings record

    Director or officer change

  29. 15 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 15 Jun 2023Filings record

    Director or officer change

  31. 20 Apr 2023Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['NAT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12623749
  32. 20 Oct 2022Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CPT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12628318
  33. 4 Oct 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 4 Oct 2022Filings record

    Director or officer change

  35. 20 Jul 2022Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TAX']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12630559
  36. 21 Apr 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 21 Apr 2022Filings record

    Director or officer change

  38. 11 Mar 2022Insiders record

    667, L.P. (director) and 5 other(s) bought 389,080 shares of INCY ($28.1M) (dated 10 Mar 2022)

  39. 23 Feb 2022Insiders record

    BAKER FELIX (director) and 5 other(s) bought 525,804 shares of INCY ($35.7M) (dated 22 Feb 2022)

  40. 15 Feb 2022Insiders record

    BAKER JULIAN (director) and 5 other(s) bought 1,598,374 shares of INCY ($107.0M) (dated 14 Feb 2022)

Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.

Not listed: 342 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000879169
Ticker
INCY
Domain
incyte.com
Employer name
Incyte Corporation (1 unverified)
Hq location
DE|WILMINGTON|19803 (1 unverified)
Lobbying client
incyte
Name
Escient Pharmaceuticals Australia Pty Ltd, Escient Pharmaceuticals, Inc, Incyte Biosciences Australia Pty Ltd, Incyte Biosciences Austria GmbH and 28 more
Wikidata
Q6015591
Wikipedia
Incyte
  • DOL H-1B labor condition applications and PERM certifications613 data points2 Mar 2020 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)7 records, 84 data points1 Nov 2019 to 30 Sep 2026
  • SEC Form 13F institutional holdings2 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)144 records19 Jan 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1104 data points31 Dec 2008 to 22 Oct 2026
  • SEC Form 4 insider transactions247 records, 768 data points8 Jan 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026